Breathing problem in parkinson diseases.pptx

Breathing problem in parkinson diseases.pptx

1. Breathing problem in parkinson diseases

2. Patients suffering from PD, at an early asymptomatic stage, describe a variety of symptoms of varying severity related to the respiratory system, including: dyspnea, upper airway symptoms, or stridor. Little is known about the general pathogenesis of this condition, most of the problems detected in PD are believed to be directly caused by neurodegeneration and its consequences - namely a lack of proper motor control ( Torsney and Forsyth 2017). Pokusa, 2019. Respiratory Function and Dysfunction in Parkinson-Type  Neurodegeneration .  https://doi.org/10.33549/physiolres.934405

3. Pathological processes such as bradykinesia , discoordination , contraction and weakness of the inspiratory muscles lead to restrictive ventilation dysfunction. The frequency of restrictive respiratory dysfunction in PD patients varies from 28% to 94%, depending on homogeneity in the study, disease progression, or treatment with anti-Parkinson's drugs. Pokusa, 2019. Respiratory Function and Dysfunction in Parkinson-Type  Neurodegeneration .  https://doi.org/10.33549/physiolres.934405

4. Reduced vital capacity, which is the main sign of restrictive disorders. Restrictive disorders are less responsive to dopaminergic therapy. Studies on the impact of levodopa on types of respiratory problems vary widely due to variations in patient age, disease progression and duration, and variations in techniques for assessing respiratory complications (Weiner et al. 1978, Pal et al. 2007, Torsney and Forsyth 2017). Pokusa, 2019. Respiratory Function and Dysfunction in Parkinson-Type  Neurodegeneration .  https://doi.org/10.33549/physiolres.934405

5. Patients suffering from PD also show decreased ability to respond to hypercapnia . This phenomenon can be explained by the fact that in the early stages of PD there is selective degeneration of dopaminergic neurons in the medulla, with CO2 and / or O2 regulation ( Seccombe et al. 2011). Km Torsney, 2017. respiratory disfuction in parkinson diseases. volume 47 edisi 1 © Royal College of Physicians of Edinburgh

6. levodopa and ergot-derived dopamine agonists may also cause respiratory dysfunction in Pd. Levodopa-induced diaphragmatic dyskinesia can cause rapid severe and severe dyspnea Km Torsney, 2017. respiratory disfuction in parkinson diseases. volume 47 edisi 1 © Royal College of Physicians of Edinburgh

7. Pleuropulmonary fibrosis and pleural effusion have been reported in patients using ergot-derived dopamine agonists. usually develops within three years of starting this treatment, although this has been reported in patients after 11 years. Km Torsney, 2017. respiratory disfuction in parkinson diseases. volume 47 edisi 1 © Royal College of Physicians of Edinburgh